The drug name is more useful than the category
GHRH stands for growth hormone-releasing hormone; GRF, or growth hormone-releasing factor, is another term used for this signal. The shared terminology can make two treatments sound interchangeable when they are not.
Sermorelin corresponds to the active 1–29 portion of GHRH. Tesamorelin uses a modified 44-amino-acid sequence. Neither is simply a different brand name for the other. Neither is growth hormone replacement itself.
When a study title says only “growth hormone-releasing hormone,” look at the methods for the actual medication. This small step prevents one of the most consequential errors in peptide comparisons: assigning a promising result to a drug the researchers never gave.
What tesamorelin’s approval actually covers
The FDA label for Egrifta WR describes a specific use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It expressly excludes weight-loss management and says long-term cardiovascular safety has not been established.
That is a meaningful approval, but a bounded one. It does not make tesamorelin a general recommendation for someone who wants to lose belly fat. It also does not establish that sermorelin produces the same result in that population or in anyone else.
Ask which clinical problem is being treated before comparing a product’s reputation or price. A specific diagnosis and an appearance goal are different starting points for evaluating the same paper.
A comparison that keeps the boundaries visible
| Question | Sermorelin | Tesamorelin |
|---|---|---|
| Same medication? | No; GHRH(1–29) | No; a modified longer GHRH analog |
| Which cognition paper used it? | Vitiello, 2006 | Baker, 2012 |
| Does the other drug’s result apply automatically? | No | No |
| Can a different formulation use the same instructions? | Follow the actual prescription and pharmacy label | Follow the specific product’s label |
A stronger evidence base for a particular tesamorelin indication is not proof that it is “stronger” for every goal. Strength is too vague here: hormone response, fat distribution, symptoms, and adverse effects are separate questions.
The cognition studies illustrate the problem
The 2006 sermorelin study and the 2012 tesamorelin study both examined cognitive outcomes in older adults. Reading them together can inform research into this pathway. Combining them into one pool of “sermorelin results” misidentifies the intervention.
The problem becomes larger when a secondary summary lifts a body-composition result from a cognition paper and presents it as a general weight-loss benefit. The reader has now lost both the drug identity and the original research question.
Our cognition review separates those trials. For body-composition claims, see the sermorelin weight-loss evidence. Neither article treats a related molecule as a substitute for direct data.
The exact product still matters
Even within tesamorelin, the Egrifta WR label distinguishes its preparation and instructions from Egrifta SV. That is a reminder that a familiar ingredient name does not tell you everything needed to use a medication correctly.
A compounded preparation raises a separate question: what evidence applies to that formulation? FDA does not approve compounded drugs before marketing. An approved tesamorelin product’s status does not confer approval on compounded sermorelin or on a mixture sold under a wellness label.
Do not borrow mixing, storage, or injection instructions from another product’s page. Ask the dispensing pharmacist about the prescription actually supplied. Our storage and travel guide explains how to keep that information attached to the right product.
How to evaluate a recommendation
If a clinician proposes one of these medications, ask for a clear connection between your problem and the evidence: “Which study or indication fits my situation, and what outcome should we use to evaluate it?” That is more informative than asking which peptide is best.
Then separate three decisions: whether treatment is appropriate, which medication has relevant evidence, and which specific product is being prescribed. A subscription comparison belongs after those questions, not in place of them.
There is no universal winner in this comparison. Tesamorelin has a defined approved indication; sermorelin has its own limited research and historical regulatory context. Keeping those facts separate makes a consultation more useful and a marketing claim easier to assess.
Sources & further reading
Sources reviewed October 2026. Provider prices and terms may change.